IP Library Granted Patent US 11,149,079
Granted Patent B2
US 11,149,079 · App. 15/328,996 · Granted Oct 19, 2021

Process for the preparation of immunoglobulin G (IgG)

Inventors: John More (Elstree, GB); Tara Dolan (Elstree, GB)
Assignee: BIO PRODUCTS LABORATORY LIMITED
C07K16/065
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,149,079
App. No.
15/328,996
Granted
Oct 19, 2021
Kind
B2
Abstract

The present invention is directed to processes for extracting IgG from an unused waste precipitate produced during normal plasma fractionation processes via a separate fractionation process, thereby increasing the overall yield of IgG from blood plasma.

Claims (27)

1. A method for extracting IgG from a waste precipitate fraction, the method comprising homogenizing the waste precipitate fraction with a suitable solvent for a period sufficient to extract IgG from the precipitate into the solvent, wherein the waste precipitate fraction is produced during plasma fractionation and separated from a main IgG manufacturing process stream, and wherein the suitable solvent is the same as a solvent used in a fractionation step which produced the waste precipitate wherein the extracted IgG comprises not less than 85% monomer and dimer and not more than 10 wt. % polymer and/or aggregate, and wherein the method for extracting IgG from the waste precipitate fraction does not involve any chromatographic steps.

2. A method according to claim 1 , wherein the waste precipitate fraction is produced during a fractionation step to produce a liquid fraction (supernatant) containing IgG.

3. A method according to claim 2 , wherein the liquid fraction is selected from the group consisting of Cohn supernatant III, Cohn supernatant I+III, Kistler & Nitschmann supernatant B, Kistler & Nitschmann supernatant B+I, modified Kistler & Nitschmann supernatant B, and modified Kistler & Nitschmann supernatant B+I.

4. A method according to claim 1 , wherein the waste precipitate fraction is selected from the group consisting of Cohn fraction III, Cohn fraction I+III, Kistler & Nitschmann precipitate B, Kistler & Nitschmann precipitate B+I, modified Kistler & Nitschmann precipitate B, and modified Kistler & Nitschmann precipitate B+I.

5. A method according to claim 1 , wherein the solvent is buffered aqueous ethanol.

6. A method according to claim 5 , wherein the solvent is an aqueous buffer containing about 13 vol. % to about 17 vol. % ethanol.

7. A method according to claim 5 , wherein the solvent is buffered using phosphate and/or acetate buffer.

8. A method according to claim 1 , wherein the ratio of waste precipitate fraction to solvent is from about 1:2 to about 1:10.

9. A method according to claim 1 , wherein the solvent containing extracted IgG is separated from any remaining waste precipitate solids.

10. A method according claim 9 , wherein the solvent containing extracted IgG is separated from remaining waste precipitate solids by filtration or centrifugation.

11. A method according to claim 1 , wherein the extracted IgG is combined with IgG obtained from the main IgG manufacturing process stream.

12. A method according to claim 1 , wherein the method for extracting IgG from the waste precipitate fraction does not involve any chromatographic steps.

13. A method according to claim 1 , wherein the extracted IgG obtained from the waste precipitate is further processed to produce a pharmaceutical IgG product.

14. A method according to claim 13 , wherein the further processing to produce a pharmaceutical IgG product comprises precipitation of the extracted IgG from the solvent.

15. A method according to claim 14 , wherein the precipitation is achieved by adjusting one or more of ethanol concentration, temperature and pH.

16. A method according to claim 14 , wherein the precipitation yields an IgG enriched Fraction II precipitate.

17. A method according to claim 14 , wherein the resulting precipitate is combined with an IgG rich fraction from the main IgG manufacturing process stream.

18. A method for the preparation of IgG comprising:

a) recovering precipitate and supernatant from a modified Kistler and Nitschmann B+I fractionation process;

b) homogenising the precipitate obtained in step a) and extracting IgG therefrom by mixing with 17 vol. % aqueous ethanol in acetate and/or phosphate buffer at 0° C. for 1 to 3 hours, and wherein extracting IgG does not involve any chromatographic steps; and then

c) separating the buffer containing extracted IgG from any remaining precipitate, wherein the extracted IgG comprises not less than 85% monomer and dimer and not more than 10 wt. % polymer and/or aggregate.

19. The method according to claim 18 , further comprising:

d) combining the buffer containing extracted IgG obtained in step c) with the modified Kistler and Nitschmann B+I supernatant obtained in step a).

20. The method according to claim 18 , wherein step c) is performed via filtration and wherein the method further comprises:

e) incubating the extracted IgG in aqueous ethanol according to the conditions for modified Kistler and Nitschmann Fraction II precipitation; and

f) recovering the resulting IgG-enriched Fraction II precipitate.

21. A method according to claim 1 , wherein the extracted IgG product comprises a purity of not less than 90% gammaglobulin.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 25, 2017
From: MORE, JOHN; DOLAN, TARA
To: BIO PRODUCTS LABORATORY LIMITED
Reel/Frame 041481/0264 →
Priority Claims (1)
GB 1413227 · Jul 25, 2014 · national
Continuity (1)
Related Publication 20170247433A1 · Aug 31, 2017